Trials / Completed
CompletedNCT01703026
Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses
Contrast Enhanced EUS Using Definity in the Evaluation of Pancreatic Cancer and Pancreatic Masses
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 33 (actual)
- Sponsor
- Changi General Hospital · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Contrast enhanced EUS with the sonographic contrast agent DEFINITY™ has the potential to detect pancreatic cancer at an earlier stage, to improve current method of T staging and assessment of surgical resectability and also to distinguish between benign and malignant pancreatic masses. All these will translate into better clinical outcome, and also avoid unnecessary surgery in situations of unresectable cancers.
Conditions
Timeline
- Start date
- 2009-08-01
- Completion
- 2011-10-01
- First posted
- 2012-10-10
- Last updated
- 2012-10-10
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT01703026. Inclusion in this directory is not an endorsement.